Linked Life Data

12562558

Source:http://linkedlifedata.com/resource/pubmed/id/12562558

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-2-3
pubmed:abstractText
Levalbuterol, the pure (R)-isomer of racemic albuterol, is a new therapeutic option for patients with asthma. Racemic albuterol comprises a 50:50 mixture of (R)- and (S)-albuterol, with (R)-albuterol conferring all of the bronchodilator effects of the racemate. Numerous preclinical and in vitro studies have indicated that (S)-albuterol is not an inert isomer, but may have proinflammatory effects. Results from clinical trials in adults and children with asthma have demonstrated that 0.63 mg levalbuterol provides effective bronchodilation with lower b-mediated side effects compared with 2.5 mg racemic albuterol. In the emergency department, levalbuterol provided greater bronchodilation and significantly reduced hospital admissions compared with racemic albuterol. Recent studies have supported that levalbuterol use in acute settings may reduce the cost of asthma treatment by decreasing the total treatments and subsequent respiratory therapy resources. Levalbuterol provides heath care professionals with a safe, effective, and potentially cost-saving alternative to racemic albuterol for the treatment of patients with asthma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1529-7322
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
172-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Single-isomer levalbuterol: a review of the acute data.
pubmed:affiliation
Emergency Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA. rnowak1@hfhs.org
pubmed:publicationType
Journal Article, Comparative Study, Review